Johnson & Johnson and Protagonist won FDA approval for Icotyde (icotrokinra), the first oral IL‑23 receptor antagonist cleared for moderate‑to‑severe plaque psoriasis in adults and adolescents. The approval followed four phase III trials that enrolled about 2,500 patients and met primary efficacy and safety endpoints. The lead sentence: regulators approved the oral IL‑23 pill, positioning it as a potential switch option to injectable biologics. Icotyde’s clinical program included head‑to‑head and site‑specific studies versus active comparators; J&J projects peak sales in excess of $5 billion and expects the pill to expand the addressable market by offering a daily oral alternative to injectables. The label covers patients 12 years and older meeting systemic therapy criteria. The decision will influence prescribing patterns and payer negotiations given oral convenience vs. parenteral biologics. Long‑term safety, durability and comparative effectiveness data will determine how many patients switch from injections to the new pill.